What's Your Top Stock Pick for 2018?
As the year comes to a close and financial activity winds down for the year, what is everyone's top stock pick for 2018? What are your justifications for your pick?
At the end of 2018 we can look back and see which stocks performed the best.
See WSO monkeys' picks from 2017 here
Tiger16, hey, look at the bright side, at least you didn't get a ton of monkey shit thrown at you...here is my best guess on threads that might be helpful:
Who will rescue this thread? rge signposts Alexandre-Perrin
I hope those threads give you a bit more insight.
VALE [NYSE] - Vale S.A.
CXW [NYSE] - CoreCivic, Inc.
FPI [NYSE] - Farmland Partners Inc.
GE [NYSE] - General Electric Company
From last year valeant.
I don’t see a reason to make a call on an arbitrary start date like the new year. I will hit a pitch when it’s presented.
Recent buys have been off-shore drillers but not a ton. If oil is going to stay up here or ideally find another $5-10 then some money should be flowing into their businesses.
FB always FB
220 at least by 2018 YE
Twitter GoPro HYT IHF ARKK
Ethereum
I think my pick my have won last year....
I'm long on PTLA and have doubled down on ITM and OTM June Calls. Holding 45 calls right now I think.
There's the saying 'Don't bet on bad management,' Well, I've been betting on it and getting cucked in the mean time. Bill Lis and his team at PTLA have shown an astounding ability to overlook large details like changes in polymorph manufacturing that set back the commercial launch of Bevyxxa by months.
But who cares, the science behind Andexxa is SOLID and they have a promising oncology drug in the works too. Andexxa is the only drug out there that can do what it does (reverse the effects of blood thinners) in just minutes. Over 1,000 people die a month in the United States do to side effects of blood thinners and everyone who takes a blood thinner would love to have a reversal agent with them.
The FDA recently extended the approval date for PTLA by another 90 days (so May) which has created a great opportunity to BTFD.
Best case scenario Andexxa gets approved and Bevyxxa has a good commercial launch, derisking the company and diverting cash flow from R&D to marketing these drugs and then they get acquired.
$100 EoY. +100% returns incoming.
Ea ab quasi inventore. Iste quo autem cumque quo similique accusantium repellat. Et autem nobis ducimus molestiae repudiandae doloremque. Totam dolores laudantium dolorem aut.
Corrupti adipisci qui ad. Temporibus magnam quia et dolor sunt.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...